In recent years, bispecific antibodies (BsAbs) have emerged as one of the most promising innovations in cancer immunotherapy. From hematologic malignancies to solid tumors, an increasing number of bispecific antibody candidates have entered clinical development and continue to demonstrate encouraging results.

In the treatment of head and neck cancers, bispecific antibodies offer the potential to overcome the limitations of conventional therapies and single-agent immunotherapy through their unique mechanisms of action, providing patients with new therapeutic options.

Will bispecific antibodies reshape the treatment landscape for head and neck cancer? DengYueMed reviews the latest research progress, explaining their mechanisms of action, clinical advantages, and future development prospects.

---

What Are Bispecific Antibodies?

Bispecific antibodies are engineered antibodies capable of simultaneously recognizing and binding to two different antigens or two distinct epitopes. Compared with conventional monoclonal antibodies, they offer greater functional versatility.

Several types of bispecific antibodies are currently under investigation for head and neck cancer, including:

• EGFR×CD3 bispecific antibodies – Bridge tumor cells and T cells to activate immune-mediated tumor killing.
• PD-L1×TGF-β bispecific antibodies – Simultaneously relieve immune suppression and remodel the tumor microenvironment.
• VEGF×PD-1/PD-L1 bispecific antibodies – Combine anti-angiogenic activity with immune activation.
• HER2-targeted bispecific antibodies – Designed for patients with HER2-expressing tumors.

These innovative designs allow a single therapeutic agent to exert multiple antitumor mechanisms simultaneously.

---

Why Does Head and Neck Cancer Need New Treatment Strategies?

Head and neck squamous cell carcinoma (HNSCC) is one of the most common malignancies worldwide.

Patients continue to face several major clinical challenges, including:

• High rates of local recurrence
• Frequent lymph node metastasis
• Poor overall prognosis in advanced disease
• Limited benefit from PD-1 inhibitors in some patients
• A highly complex immunosuppressive tumor microenvironment

Although PD-1-based immunotherapy has significantly improved outcomes for some patients, many individuals experience limited or no response. Consequently, developing more effective immunotherapeutic strategies has become a major research priority, with bispecific antibodies representing one of the most promising approaches.

---

How Could Bispecific Antibodies Change the Treatment of Head and Neck Cancer?

1. Simultaneously Activating the Immune System

Traditional PD-1 antibodies primarily work by releasing the “brakes” on T cells.

In contrast, EGFR×CD3 bispecific antibodies not only recognize tumor cells but also actively recruit T cells into close proximity with cancer cells, facilitating highly targeted cytotoxic activity.

Potential advantages include:

• Activating a larger population of T cells
• Increasing T-cell infiltration into tumors
• Enhancing cytotoxic function
• Improving overall antitumor activity

This strategy may be particularly beneficial for patients with poorly infiltrated (“immune-cold”) tumors.

---

2. Targeting Multiple Resistance Mechanisms Simultaneously

Head and neck cancers possess complex immunosuppressive networks, and blocking PD-1 alone is often insufficient to fully restore antitumor immunity.

For example:

• TGF-β promotes immune suppression.
• VEGF restricts immune-cell infiltration into tumors.
• EGFR overexpression drives tumor proliferation and survival.

Bispecific antibodies can simultaneously inhibit multiple signaling pathways within a single treatment, reducing immune escape and potentially improving therapeutic efficacy.

---

3. Potentially Improving Objective Response Rate (ORR)

Multiple clinical studies have demonstrated that bispecific antibodies:

• Exhibit encouraging antitumor activity in several solid tumors.
• May remain effective in patients who have developed resistance to PD-1 inhibitors.
• Have achieved promising objective response rates (ORR) and disease control rates (DCR) in early clinical studies.

Although clinical evidence in head and neck cancer is still emerging, the preliminary findings are highly encouraging.

---

Which Clinical Developments Deserve Attention?

EGFR×CD3 Bispecific Antibodies

This is currently one of the most actively investigated approaches.

Key objectives include:

• Activating T cells
• Precisely targeting EGFR-positive tumors
• Improving outcomes in patients who have failed PD-1 therapy

Several Phase I and Phase II clinical trials are currently underway.

---

PD-L1×TGF-β Bispecific Antibodies

These agents are designed to simultaneously:

• Block PD-L1-mediated immune escape
• Inhibit TGF-β-driven immunosuppression
• Remodel the tumor microenvironment

This strategy may be particularly suitable for patients with immunologically “cold” tumors.

---

VEGF×PD-1 Bispecific Antibodies

Emerging evidence suggests that anti-angiogenic therapy not only improves tumor vascularization but may also facilitate immune-cell infiltration into tumors.

Consequently, dual inhibition of VEGF and PD-1 may further enhance the effectiveness of immunotherapy.

---

What Are the Potential Advantages of Bispecific Antibodies?

Feature	Monoclonal Antibodies	Bispecific Antibodies
Number of targets	One	Two
Immune activation	Moderate	Stronger
Ability to overcome resistance	Limited	Greater potential
Mechanism of action	Often requires combination therapy	Multiple mechanisms within a single drug
Improvement of tumor microenvironment	Limited	More comprehensive

These characteristics position bispecific antibodies as a promising platform for future precision oncology.

---

What Challenges Still Remain?

Despite their significant promise, several important challenges remain.

Safety Management

Some bispecific antibodies may increase the risk of immune-related adverse events, including cytokine release syndrome (CRS). Optimizing dosing schedules and administration strategies will be essential.

Patient Selection

Not every patient is likely to benefit equally. Identifying reliable predictive biomarkers remains a major research priority.

Clinical Evidence

Most bispecific antibodies are currently being evaluated in Phase I or Phase II clinical trials. Additional Phase III studies are needed to confirm long-term efficacy and safety.

Manufacturing Complexity and Cost

Because of their sophisticated molecular structures, bispecific antibodies are more challenging and expensive to develop and manufacture than conventional monoclonal antibodies, posing additional commercialization challenges.

---

Will Bispecific Antibodies Become the New Standard of Care for Head and Neck Cancer?

At present, bispecific antibodies are unlikely to completely replace existing treatment approaches.

However, they have demonstrated considerable potential to:

• Offer new therapeutic options for patients with limited response or resistance to PD-1 inhibitors.
• Improve the precision and potency of cancer immunotherapy.
• Work synergistically with radiotherapy, chemotherapy, targeted therapies, and antibody-drug conjugates (ADCs).
• Advance head and neck cancer treatment toward more personalized and effective therapeutic strategies.

As more pivotal clinical trial data become available and next-generation bispecific antibodies receive regulatory approval, these agents are expected to become an increasingly important component of comprehensive head and neck cancer management.

---

Conclusion

Bispecific antibodies are opening new possibilities in the treatment of head and neck cancer. Innovative designs such as EGFR×CD3 and PD-L1×TGF-β bispecific antibodies not only enhance immune recognition and destruction of tumor cells but may also help overcome resistance to current immunotherapies in some patients.

Although additional high-quality clinical evidence is still needed, bispecific antibodies have already emerged as one of the most promising areas of research and development in head and neck oncology, with the potential to significantly reshape future treatment paradigms.

As innovative immunotherapies continue to evolve, DengYueMed remains committed to tracking the latest advances in oncology and providing global healthcare professionals and patients with timely insights into cutting-edge treatment options and access to innovative medicines from China.